OTCMKTS:IMUCD

ImmunoCellular Therapeutics Competitors

$0.48
-0.03 (-5.88 %)
(As of 04/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.48
Now: $0.48
$0.51
50-Day Range
$0.31
MA: $0.60
$0.87
52-Week Range
$0.16
Now: $0.48
$0.51
Volume7,298 shs
Average Volume6,605 shs
Market Capitalization$2.01 million
P/E RatioN/A
Dividend YieldN/A
Beta1.63

Competitors

ImmunoCellular Therapeutics (OTCMKTS:IMUCD) Vs. GBIM, PARNF, PVTTF, WCUI, KAYS, and ISCO

Should you be buying IMUCD stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to ImmunoCellular Therapeutics, including GlobeImmune (GBIM), Parnell Pharmaceuticals (PARNF), Pivotal Therapeutics (PVTTF), Wellness Center USA (WCUI), Kaya (KAYS), and International Stem Cell (ISCO).

GlobeImmune (OTCMKTS:GBIM) and ImmunoCellular Therapeutics (OTCMKTS:IMUCD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for GlobeImmune and ImmunoCellular Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
GlobeImmune0000N/A
ImmunoCellular Therapeutics0000N/A

Earnings and Valuation

This table compares GlobeImmune and ImmunoCellular Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GlobeImmuneN/AN/AN/AN/AN/A
ImmunoCellular TherapeuticsN/AN/A$-14,310,000.00N/AN/A

Volatility and Risk

GlobeImmune has a beta of 2.04, suggesting that its share price is 104% more volatile than the S&P 500. Comparatively, ImmunoCellular Therapeutics has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500.

Profitability

This table compares GlobeImmune and ImmunoCellular Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GlobeImmuneN/AN/AN/A
ImmunoCellular TherapeuticsN/AN/AN/A

Summary

GlobeImmune beats ImmunoCellular Therapeutics on 1 of the 1 factors compared between the two stocks.

Parnell Pharmaceuticals (OTCMKTS:PARNF) and ImmunoCellular Therapeutics (OTCMKTS:IMUCD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Parnell Pharmaceuticals and ImmunoCellular Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Parnell Pharmaceuticals0000N/A
ImmunoCellular Therapeutics0000N/A

Profitability

This table compares Parnell Pharmaceuticals and ImmunoCellular Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Parnell PharmaceuticalsN/AN/AN/A
ImmunoCellular TherapeuticsN/AN/AN/A

Earnings and Valuation

This table compares Parnell Pharmaceuticals and ImmunoCellular Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Parnell PharmaceuticalsN/AN/AN/AN/AN/A
ImmunoCellular TherapeuticsN/AN/A$-14,310,000.00N/AN/A

Volatility and Risk

Parnell Pharmaceuticals has a beta of 5, suggesting that its share price is 400% more volatile than the S&P 500. Comparatively, ImmunoCellular Therapeutics has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500.

Summary

Parnell Pharmaceuticals beats ImmunoCellular Therapeutics on 1 of the 1 factors compared between the two stocks.

Pivotal Therapeutics (OTCMKTS:PVTTF) and ImmunoCellular Therapeutics (OTCMKTS:IMUCD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Pivotal Therapeutics and ImmunoCellular Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pivotal Therapeutics0000N/A
ImmunoCellular Therapeutics0000N/A

Profitability

This table compares Pivotal Therapeutics and ImmunoCellular Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pivotal TherapeuticsN/AN/AN/A
ImmunoCellular TherapeuticsN/AN/AN/A

Earnings and Valuation

This table compares Pivotal Therapeutics and ImmunoCellular Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pivotal TherapeuticsN/AN/AN/AN/AN/A
ImmunoCellular TherapeuticsN/AN/A$-14,310,000.00N/AN/A

Volatility & Risk

Pivotal Therapeutics has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Comparatively, ImmunoCellular Therapeutics has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500.

Summary

ImmunoCellular Therapeutics beats Pivotal Therapeutics on 1 of the 1 factors compared between the two stocks.

Wellness Center USA (OTCMKTS:WCUI) and ImmunoCellular Therapeutics (OTCMKTS:IMUCD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Wellness Center USA and ImmunoCellular Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Wellness Center USA0000N/A
ImmunoCellular Therapeutics0000N/A

Profitability

This table compares Wellness Center USA and ImmunoCellular Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Wellness Center USAN/AN/A-1,809.19%
ImmunoCellular TherapeuticsN/AN/AN/A

Institutional & Insider Ownership

0.1% of Wellness Center USA shares are owned by institutional investors. 14.1% of Wellness Center USA shares are owned by company insiders. Comparatively, 3.3% of ImmunoCellular Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Wellness Center USA and ImmunoCellular Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Wellness Center USA$30,000.00228.21$-2,390,000.00N/AN/A
ImmunoCellular TherapeuticsN/AN/A$-14,310,000.00N/AN/A

Wellness Center USA has higher revenue and earnings than ImmunoCellular Therapeutics.

Risk & Volatility

Wellness Center USA has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, ImmunoCellular Therapeutics has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500.

Summary

Wellness Center USA beats ImmunoCellular Therapeutics on 4 of the 6 factors compared between the two stocks.

Kaya (OTCMKTS:KAYS) and ImmunoCellular Therapeutics (OTCMKTS:IMUCD) are both small-cap consumer discretionary companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Earnings and Valuation

This table compares Kaya and ImmunoCellular Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kaya$1.01 million6.71$7.80 millionN/AN/A
ImmunoCellular TherapeuticsN/AN/A$-14,310,000.00N/AN/A

Kaya has higher revenue and earnings than ImmunoCellular Therapeutics.

Profitability

This table compares Kaya and ImmunoCellular Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kaya-1,558.07%N/A-586.93%
ImmunoCellular TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and price targets for Kaya and ImmunoCellular Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kaya01002.00
ImmunoCellular Therapeutics0000N/A

Volatility & Risk

Kaya has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500. Comparatively, ImmunoCellular Therapeutics has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500.

Summary

ImmunoCellular Therapeutics beats Kaya on 3 of the 5 factors compared between the two stocks.

International Stem Cell (OTCMKTS:ISCO) and ImmunoCellular Therapeutics (OTCMKTS:IMUCD) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, analyst recommendations, profitability and earnings.

Earnings & Valuation

This table compares International Stem Cell and ImmunoCellular Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
International Stem Cell$9.47 million0.57$-4,260,000.00N/AN/A
ImmunoCellular TherapeuticsN/AN/A$-14,310,000.00N/AN/A

International Stem Cell has higher revenue and earnings than ImmunoCellular Therapeutics.

Profitability

This table compares International Stem Cell and ImmunoCellular Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
International Stem Cell-55.56%N/A-72.21%
ImmunoCellular TherapeuticsN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations for International Stem Cell and ImmunoCellular Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
International Stem Cell0000N/A
ImmunoCellular Therapeutics0000N/A

Volatility & Risk

International Stem Cell has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, ImmunoCellular Therapeutics has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500.

Summary

ImmunoCellular Therapeutics beats International Stem Cell on 3 of the 5 factors compared between the two stocks.


ImmunoCellular Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
GlobeImmune logo
GBIM
GlobeImmune
0.5$1.53-17.4%$7.25 millionN/A0.00
Parnell Pharmaceuticals logo
PARNF
Parnell Pharmaceuticals
0.5$0.36-0.0%$7.20 millionN/A0.00
Pivotal Therapeutics logo
PVTTF
Pivotal Therapeutics
0.6$0.08-0.0%$7.15 millionN/A0.00News Coverage
Wellness Center USA logo
WCUI
Wellness Center USA
0.5$0.06-6.7%$6.39 million$30,000.000.00Gap Down
KAYS
Kaya
0.7$0.47-8.1%$6.23 million$1.01 million0.00Gap Up
International Stem Cell logo
ISCO
International Stem Cell
0.8$0.72-4.2%$5.65 million$9.47 million0.00Gap Down
Intellipharmaceutics International logo
IPCIF
Intellipharmaceutics International
0.6$0.23-4.8%$5.19 million$3.48 million-1.92News Coverage
Gap Up
BCTXF
BriaCell Therapeutics
0.0N/AN/A$4.59 millionN/A-0.01
FutureWorld logo
FWDG
FutureWorld
0.5$0.00-16.7%$4.56 millionN/A0.00Gap Down
American Bio Medica logo
ABMC
American Bio Medica
0.5$0.11-4.3%$4.49 million$3.65 million0.00Decrease in Short Interest
AMBS
Amarantus BioScience
0.0$0.01-1.8%$4.13 millionN/A0.00Increase in Short Interest
Gap Up
AKRXQ
Akorn
0.1$0.03-0.0%$3.60 million$682.43 million-0.01
VG Life Sciences logo
VGLS
VG Life Sciences
0.0$0.01-1.3%$3.45 millionN/A0.00Increase in Short Interest
News Coverage
Gap Up
RSPI
RespireRx Pharmaceuticals
0.5$0.04-5.6%$3.00 millionN/A-0.09
Immune Pharmaceuticals logo
IMNPQ
Immune Pharmaceuticals
0.0$0.17-15.2%$2.94 millionN/A0.00High Trading Volume
Increase in Short Interest
News Coverage
Gap Down
INNVD
Innovus Pharmaceuticals
0.6N/AN/A$2.90 million$23.99 million-0.72Gap Down
NSPX
Inspyr Therapeutics
0.5$0.02-1.3%$2.34 millionN/A0.00Gap Down
Boston Therapeutics logo
BTHE
Boston Therapeutics
0.5$0.02-2.6%$2.22 million$20,000.00-0.98
VVUSQ
VIVUS
0.6$0.12-0.0%$2.10 million$69.76 million-0.04
Capstone Therapeutics logo
CAPS
Capstone Therapeutics
0.8$36.01-5.6%$1.95 million$2 million0.00High Trading Volume
Gap Down
WWHC
W World
0.8$6.09-0.0%$1.80 millionN/A0.00Increase in Short Interest
News Coverage
Earth Science Tech logo
ETST
Earth Science Tech
0.5$0.03-21.6%$1.70 million$530,000.000.00Gap Down
ImmunoCellular Therapeutics logo
IMUC
ImmunoCellular Therapeutics
0.0$0.51-5.9%$1.69 millionN/A0.00
Cardax logo
CDXI
Cardax
0.0$2.00-5.0%$1.67 million$710,000.000.00
MLNTQ
Melinta Therapeutics
0.2$0.11-0.0%$1.51 million$96.43 million0.00
Achaogen logo
AKAOQ
Achaogen
0.6$0.03-0.4%$1.31 million$8.73 million0.00Gap Up
Cotinga Pharmaceuticals logo
COTQF
Cotinga Pharmaceuticals
0.4$0.25-79.4%$1.12 millionN/A-2.76Decrease in Short Interest
News Coverage
Gap Down
TetraLogic Pharmaceuticals logo
TLOG
TetraLogic Pharmaceuticals
0.5$0.04-19.7%$1.11 millionN/A0.00Gap Up
AOXG
Aoxing Pharmaceutical
0.5$0.02-10.4%$1.05 millionN/A0.00Gap Up
Propanc Biopharma logo
PPCB
Propanc Biopharma
0.7$0.21-4.8%$1.03 millionN/A0.00Decrease in Short Interest
Gap Up
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.07-2.1%$970,000.00N/A0.00Increase in Short Interest
News Coverage
Gap Up
SPHS
Sophiris Bio
0.1$0.03-0.4%$963,000.00N/A0.00Increase in Short Interest
News Coverage
Gap Up
AOLS
Aeolus Pharmaceuticals
0.8$0.01-12.9%$928,000.00N/A0.00Increase in Short Interest
News Coverage
ATRX
Adhera Therapeutics
0.0$0.08-0.0%$872,000.00$250,000.000.00
Spotlight Innovation logo
STLT
Spotlight Innovation
0.5$0.01-125.0%$772,000.00N/A0.00Gap Up
Sienna Biopharmaceuticals logo
SNNAQ
Sienna Biopharmaceuticals
0.5$0.02-36.3%$749,000.00N/A0.00News Coverage
Gap Up
PXYN
Praxsyn
0.6$0.00-20.0%$678,000.00N/A0.00Increase in Short Interest
Gap Down
SKVI
Skinvisible
0.7$0.15-0.0%$671,000.00$40,000.000.00
Argos Therapeutics logo
ARGSQ
Argos Therapeutics
0.6$0.05-0.0%$572,000.00$1.90 million0.00
TRPXD
Therapix Biosciences
0.0$9.15-1.0%$458,000.00N/A0.00High Trading Volume
BSPM
Biostar Pharmaceuticals
0.0$0.17-0.0%$436,000.00N/A0.00
HSTC
HST Global
0.8$0.07-0.0%$378,000.00N/A0.00
EPRSQ
EPIRUS Biopharmaceuticals
0.5$0.01-17.6%$374,000.00N/A0.00Increase in Short Interest
Gap Down
ProMetic Life Sciences logo
PFSCF
ProMetic Life Sciences
0.5$5.47-3.7%$338,000.00$36.55 million0.00News Coverage
Gap Up
PZRXQ
PhaseRx
0.2$0.03-0.0%$298,000.00N/A0.00Decrease in Short Interest
News Coverage
WDBG
Woodbrook Group
0.0$1.60-0.0%$224,000.00N/A0.00
ROSGQ
Rosetta Genomics
0.0$0.09-5.9%$124,000.00N/A0.00Gap Up
MetaStat logo
MTST
MetaStat
0.0$0.02-0.0%$118,000.00$20,000.000.00
OREXQ
Orexigen Therapeutics
0.4$0.01-26.4%$100,000.00$33.71 million0.00Gap Up
AXMP
AXM Pharma
0.2$0.00-0.0%$81,000.00N/A0.00
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.